Article
Hematology
Joshua A. Hill, Danniel Zamora, Hu Xie, Laurel A. Thur, Colleen Delaney, Ann Dahlberg, Steven A. Pergam, Wendy M. Leisenring, Michael Boeckh, Filippo Milano
Summary: Letermovir is effective in preventing clinically significant CMV infection after CBT, but there is a higher incidence of delayed-onset infections after discontinuation, requiring close monitoring and consideration for extended prophylaxis.
Article
Immunology
Marta Bodro, Carlos Cervera, Laura Linares, Belen Suarez, Jaume Llopis, Gemma Sanclemente, Sergi Casado-Llombart, Mario Fernandez-Ruiz, Maria Carmen Farinas, Sara Cantisan, Miguel Montejo, Elisa Cordero, Isabel Oriol, Maria Angeles Marcos, Francisco Lozano, Asuncion Moreno
Summary: The study aimed to assess the impact of a polygenic score on predicting CMV infection and disease in high-risk CMV transplant recipients. The polygenic score, based on several relevant genetic polymorphisms, showed potential for predicting CMV disease risk.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Dipesh Kumar Yadav, Vishnu Prasad Adhikari, Rajesh Kumar Yadav, Alina Singh, Xing Huang, Qi Zhang, Prabesh Pandit, Qi Ling, Tingbo Liang
Summary: This meta-analysis compared the outcomes of antiviral prophylaxis and preemptive therapy for the prevention of cytomegalovirus (CMV) infection in liver transplant recipients. The results showed that antiviral prophylaxis reduced the incidence of CMV infection in the high-risk group, while preemptive therapy reduced the incidence of late-onset CMV disease. There were no significant differences in other outcomes between the two interventions.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Transplantation
Rachel Hellemans, Daniel Abramowicz
Summary: CMV-related complications after kidney transplantation present a significant challenge. Tailoring preventive strategies based on individual patient risk levels can improve outcomes. CMV-specific T-cell assays can help predict CMV risk pre-transplantation. Immunosuppressive regimens including mammalian target of rapamycin inhibitors can reduce CMV risk. New antiviral agents and adoptive T-cell therapy hold promise for future treatment options.
NEPHROLOGY DIALYSIS TRANSPLANTATION
(2022)
Article
Cardiac & Cardiovascular Systems
Jennifer L. Saullo, Arthur W. Baker, Laurie D. Snyder, John M. Reynolds, Lorenzo Zaffiri, Emily M. Eichenberger, Alana Ferrari, Julie M. Steinbrink, Eileen K. Maziarz, Melissa Bacchus, Holly Berry, Stylianos A. Kakoullis, Cameron R. Wolfe
Summary: A retrospective study on thoracic transplant recipients receiving Letermovir for CMV prophylaxis showed that Letermovir was well tolerated and effective during extended prophylactic courses, with minimal adverse effects and only rare breakthrough CMV infections observed.
JOURNAL OF HEART AND LUNG TRANSPLANTATION
(2022)
Article
Immunology
Christian Heim, Philipp P. Mueller, Rene Tandler, Wida S. Cherikh, Alice E. Toll, Josef Stehlik, Michael Weyand, Kiran K. Khush, Stephan M. Ensminger
Summary: This study aimed to compare posttransplant survival in different CMV donor:recipient serologic combinations. The results showed that CMV infection was associated with reduced short- and long-term survival after heart transplantation, but did not increase the risk of cardiac allograft vasculopathy.
Article
Hematology
Scott R. Goldsmith, Muhammad Bilal Abid, Jeffery J. Auletta, Asad Bashey, Amer Beitinjaneh, Paul Castillo, Roy F. Chemaly, Min Chen, Stefan Ciurea, Christopher E. Dandoy, Miguel Angel Diaz, Ephraim Fuchs, Siddhartha Ganguly, Christopher G. Kanakry, Jennifer A. Kanakry, Soyoung Kim, Krishna Komanduri, Maxwell M. Krem, Hillard M. Lazarus, Hongtao Liu, Per Ljungman, Richard Masiarz, Carolyn Mulroney, Sunita Nathan, Taiga Nishihori, Kristin M. Page, Miguel-Angel Perales, Randy Taplitz, Rizwan Romee, Marcie Riches
Summary: This study analyzed the impact of graft source and posttransplant cyclophosphamide (PTCy) on CMV infection, finding a higher risk of CMV infection in PTCy recipients, regardless of donor. CMV infection may also affect transplant outcomes.
Review
Biotechnology & Applied Microbiology
Lorna Neill, Karl Peggs
Summary: CMV infection is mostly harmless in immunocompetent individuals, but can cause severe consequences post HSCT. Current management strategies focus on surveillance and prophylactic antiviral drugs, with the development of CMV-specific T-cell adoptive therapy as a potential future treatment. The challenge ahead is to ensure the economic viability and maximum benefit for patients in widely adopting cellular therapy.
EXPERT OPINION ON BIOLOGICAL THERAPY
(2021)
Review
Biology
Markus J. Barten, Fausto Baldanti, Alexander Staus, Christian M. Hueber, Kyriaki Glynou, Andreas Zuckermann
Summary: This meta-analysis suggests that prophylactic CMVIG treatment in solid organ transplantation patients can reduce the risk of CMV infection. This is particularly beneficial for patients at high risk of CMV infection or disease.
Review
Infectious Diseases
Fatima Allaw, Sara F. Haddad, Johnny Zakhour, Souha S. Kanj
Summary: Cytomegalovirus (CMV) is a common infection in immunocompromised patients, especially those undergoing allo-HSCT. Recent management strategies include pre-emptive treatment with frequent CMV PCR monitoring and the use of new drugs like letermovir. Treatment of CMV disease is challenging due to drug resistance, but promising results have been seen with maribavir and other alternative treatments such as immunotherapy, artesunate, and leflunomide.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2023)
Article
Immunology
Hannah Rafferty, Matthew J. Murray, Jerry C. H. Tam, Alastair Macfarlane, Colette Smith, Sheila F. Lumley, Sowsan Atabani, Jane A. McKeating, Dinesh Sharma, Matthew Reeves, David Whitmore, Paul Griffiths
Summary: Using a large data set on preemptive cytomegalovirus therapy for solid-organ transplant recipients, the study found no association between time of day of transplantation and CMV viremia, but observed increased viremia in recipients of deceased-donor transplants compared with live-donor transplants. These findings provide important insights into the factors influencing CMV infection after transplantation.
JOURNAL OF INFECTIOUS DISEASES
(2022)
Review
Immunology
Chieh-Lin Jerry Teng, Po-Nan Wang, Yee-Chun Chen, Bor-Sheng Ko
Summary: CMV infection is a common and severe complication of allo-HSCT in Taiwan due to high CMV seropositivity in the population. A CMV management strategy focusing on monitoring, prophylaxis, and treatment is proposed, including weekly monitoring with the COBAS (R) AmpliPrep system, a 14-week prophylactic course of letermovir for allo-HSCT recipients, and preemptive ganciclovir therapy when CMV viral load exceeds 1000 copies/mL. Limited availability of foscarnet is a crucial issue for patients not responsive to ganciclovir in Taiwan.
JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION
(2021)
Article
Infectious Diseases
Eleftheria Kampouri, Danniel Zamora, Erika S. Kiem, Winnie Liu, Sarah Ibrahimi, Rachel L. Blazevic, Erika A. Lovas, Louise E. Kimball, Meei-Li Huang, Keith R. Jerome, Masumi Ueda Oshima, Marco Mielcarek, Danielle M. Zerr, Michael J. Boeckh, Elizabeth M. Krantz, Joshua A. Hill
Summary: The use of letermovir for cytomegalovirus (CMV) prophylaxis has led to a decrease in broad-spectrum anti-CMV therapy. However, the impact of letermovir on human herpesvirus-6 (HHV-6) epidemiology remains unknown. This retrospective cohort study aimed to assess changes in HHV-6 detection and disease after the routine use of prophylactic letermovir in CMV-seropositive allogeneic hematopoietic cell transplant recipients.
CLINICAL MICROBIOLOGY AND INFECTION
(2023)
Article
Medicine, General & Internal
Maria Serrano-Alonso, Paloma Martin-Moreno, Gregorio Rabago, Francisco Guillen-Grima, Jose Herrero, Mirian Fernandez-Alonso
Summary: This study compared the efficacy and safety of standard and extended primary cytomegalovirus (CMV) prophylaxis in solid organ transplantation. The results showed that extending the prophylaxis did not prevent late-onset infection, but was associated with hematological toxicity.
Article
Virology
Andrea Gilioli, Andrea Messerotti, Paola Bresciani, Angela Cuoghi, Valeria Pioli, Corrado Colasante, Francesca Bettelli, Davide Giusti, Fabio Forghieri, Leonardo Potenza, Francesca Donatelli, Rachele Giubbolini, Laura Galassi, Roberto Marasca, Federico Banchelli, Roberto D'Amico, Monica Pecorari, William Gennari, Tommaso Trenti, Patrizia Comoli, Mario Luppi, Franco Narni
Summary: The study retrospectively analyzed a cohort of patients who underwent HSCT and found that CMV clinically significant infection (CS-CMVi) occurred in 48% of prophylactically treated patients, but it did not impact relapse incidence or overall survival. Additionally, the use of CMV-IG alone as prophylactic therapy did not effectively prevent CMV reactivation.
JOURNAL OF MEDICAL VIROLOGY
(2021)
Article
Immunology
Jackrapong Bruminhent, Francisco Lopez-Medrano, Brian Patrick Pogatchnik, Ellen Nascimento, Warunyu Namsiripongpun, Teerapat Yingchoncharoen, Montien Ngodngamthaweesuk, Araya Sukprapruet, Bundit Naratreekoon, Isabel Rodriguez-Goncer, Ana Hernandez, Natalia Polanco, Amado Andres, Jose Maria Aguado, Stephanie M. Pouch, Wanessa Trindade Clemente
Summary: This case involves a 69-year-old Thai woman who developed fever symptoms 9 months after undergoing orthotopic heart transplantation. Imaging revealed consolidation in the left upper lobe resembling a mass. Rhodococcus equi infection was identified through blood culture and lung tissue examination. The patient was successfully treated with a combination of antimicrobial therapy, optimization of immunosuppressants, and surgical resection.
TRANSPLANT INFECTIOUS DISEASE
(2023)
Article
Cardiac & Cardiovascular Systems
Ana Garcia-Alvarez, Isabel Blanco, Ines Garcia-Lunar, Paloma J. Jorda, Juan Rodriguez-Arias, Leticia Fernandez-Friera, Isabel Zegri, Jorge Nuche, Manuel Gomez-Bueno, Susanna Prat, Sandra Pujadas, Eduard D. Sole-Gonzalez, Maria Garcia-Cossio, Mercedes Rivas, Estefania Torrecilla, Daniel Pereda, Javier Sanchez, Pablo Garcia-Pavia, Javier Segovia-Cubero, Juan F. Delgado, Sonia Mirabet, Valentin A. Fuster, Joan Barbera, Borja Ibanez
Summary: This study aimed to evaluate the efficacy of the selective beta 3 adrenoreceptor agonist mirabegron in patients with combined pre- and post-capillary pulmonary hypertension (CpcPH). The results showed that mirabegron treatment did not reduce pulmonary vascular resistance in CpcPH patients, but significantly improved right ventricular ejection fraction.
EUROPEAN JOURNAL OF HEART FAILURE
(2023)
Article
Surgery
Carlos Jimenez-Romero, Alberto Marcacuzco, Oscar Caso, Isabel Lechuga, Alejandro Manrique, Alvaro Garcia-Sesma, Jorge Calvo, Jose Maria Aguado, Francisco Lopez-Medrano, Rafael San Juan, Iago Justo
Summary: This study aimed to compare the outcomes of patients with pyogenic liver abscess (PLA) in liver transplant (LT) and non-LT patients and determine the risk factors associated with patient survival. Among 296 adult patients, 26 had previously undergone liver transplantation (LTA group), while 263 patients were in the non-LTA population. The results showed that liver transplantation was a risk factor for in-hospital mortality, but there was no significant difference in long-term follow-up.
CLINICAL TRANSPLANTATION
(2023)
Article
Clinical Neurology
Daniel Garcia-Perez, Guillermo Garcia-Posadas, Rafael San-Juan, Patricia Branas, Irene Panero-Perez, Juan Delgado-Fernandez, Igor Paredes
Summary: Low-virulent microorganisms identified on pedicle screws by sonication fluid culture (SFC) are important causes of implant loosening. The sensitivity of SFC can be improved by sonication of explanted material, but there is a risk of contamination. Standardized diagnostic criteria for chronic low-grade spinal implant-related infection (CLGSII) have not been established. The role of serum C-reactive protein (CRP) and procalcitonin (PCT) in CLGSII has not been adequately investigated.
EUROPEAN SPINE JOURNAL
(2023)
Article
Infectious Diseases
Laura Corbella, Mario Fernandez-Ruiz, Maria Ruiz-Ruigomez, Isabel Rodriguez-Goncer, Jose Tiago Silva, Pilar Hernandez-Jimenez, Francisco Lopez-Medrano, Manuel Lizasoain, Jennifer Villa, Jose Maria Aguado, Rafael San-Juan
Summary: The production of OXA-48 carbapenemase is independently associated with poor outcomes in Klebsiella pneumoniae infection. The study found lower clinical cure rates and higher 30-day all-cause mortality in OXA-48-Kp cases compared to non-OXA-48-Kp cases. Multivariate analysis confirmed the independent association between OXA-48-Kp infection and the lack of 14-day clinical cure.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
(2023)
Article
Immunology
Mario Fernandez-Ruiz, Estefani Garcia-Rios, Natalia Redondo, Isabel Rodriguez-Goncer, Tamara Ruiz-Merlo, Patricia Parra, Virginia Sandonis, Francisco Lopez-Medrano, Rafael San Juan, Esther Gonzalez, Natalia Polanco, Amado Andres, David Navarro, Jose Maria Aguado, Pilar Perez-Romero
Summary: This study investigates the impact of cytomegalovirus (CMV)-specific antibodies on infection in kidney transplant recipients. The results suggest that CMV-AbNEIs do not have a protective role in preventing CMV infection.
JOURNAL OF INFECTIOUS DISEASES
(2023)
Article
Virology
Jose Maria Caso, Mario Fernandez-Ruiz, Francisco Lopez-Medrano, Jose Manuel Caro-Teller, Manuel Lizasoain, Rafael San-Juan, Marina Fayos Perez, Isabel Rodriguez-Goncer, Jose Tiago Silva, Jose Maria Aguado
Summary: Regardless of vaccination status, severe COVID-19 is still a significant cause of morbidity among immunocompromised patients. This study evaluated the clinical outcomes of immunocompromised patients treated with NMV/r and found a low proportion of patients with clinical worsening, but the occurrence of potential drug-to-drug interactions and treatment-emergent adverse events should still be considered.
JOURNAL OF MEDICAL VIROLOGY
(2023)
Article
Immunology
Mario Fernandez-Ruiz, Beatriz Sanchez Moreno, Javier Santiago Almeda, Isabel Rodriguez-Goncer, Tamara Ruiz-Merlo, Natalia Redondo, Francisco Lopez-Medrano, Rafael San Juan, Amado Andres, Jose Maria Aguado
Summary: Previous statin therapy had no apparent protective effect on the outcome of post-transplant bloodstream infection among kidney transplant recipients. The time to clinical cure and secondary outcomes such as fever resolution, ICU admission or renal replacement therapy requirement, and 30-day all-cause mortality did not differ significantly between statin and non-statin groups.
TRANSPLANT INFECTIOUS DISEASE
(2023)
Article
Multidisciplinary Sciences
Jose-Manuel Casas-Rojo, Juan-Miguel Anton-Santos, Jesus Millan-Nunez-Cortes, Ricardo Gomez-Huelgas, Jose-Manuel Ramos-Rincon, Manuel Rubio-Rivas, Miguel-Angel Corrales-Gonzalez, Maria-Rosa Fernandez-Madera-Martinez, Jose-Luis Beato-Perez, Francisco Arnalich-Fernandez, Cristina Gallego-Lezaun, Pablo Perez-Martinez, Sonia Molinos-Castro, Yale Tung-Chen, Manuel Madrazo, Manuel Mendez-Bailon, Daniel Monge-Monge, Gema-Maria Garcia-Garcia, Rosa Garcia-Fenoll, Noemi Gilabert, Rebeca Fuerte-Martinez, Marta Contreras-Sanchez, Nicolas Rhyman, Jorge Peris-Garcia, Carlos Lumbreras-Bermejo
Summary: This study evaluated the association between hospital admission during different waves and mortality in older patients during the COVID-19 pandemic. The results showed a significant reduction in mortality risk for patients aged 70 and older admitted during the second wave, except for those who were severely dependent on corticosteroid treatment. This effect was independent of patient characteristics, disease severity, or treatment received, suggesting a potential protective effect of a better standard of care, greater clinical expertise, or a lesser degree of healthcare system overload.
SCIENTIFIC REPORTS
(2023)
Article
Surgery
Iago Justo, Viviana Vega, Alberto Marcacuzco, Oscar Caso, Maria Garcia-Conde, Alejandro Manrique, Jorge Calvo, Alvaro Garcia-Sesma, Rafael San Juan, Mario Fernandez-Ruiz, Cristina Rivas, Maria Rosa Calero, Carlos Jimenez-Romero
Summary: A retrospective study found that the presence of underlying biliary disease or an intra-abdominal tumor and the duration of symptoms for less than 10 days upon presentation are risk factors that indicate the need for surgical therapy (ST).
LANGENBECKS ARCHIVES OF SURGERY
(2023)
Article
Infectious Diseases
Mario Agreda Fernandez, Julia Origuen, Isabel Rodriguez-Goncer, Rafael San Juan, Francisco Lopez-Medrano, Patricia Parra, Tamara Ruiz-Merlo, Natalia Redondo, Maria Angeles Orellana, Jose Maria Aguado, Mario Fernandez-Ruiz
Summary: Measuring fecal calprotectin (FC) and lactoferrin (FL) levels in patients with Clostridioides difficile infection (CDI) can predict recurrence and severity of the disease. By modifying the thresholds for assay positivity, these biomarkers can be used to individualize CDI management.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
(2023)
Review
Medicine, General & Internal
Irene Marco, Juan Carlos Lopez-Azor Garcia, Javier Gonzalez Martin, Andrea Severo Sanchez, Maria Dolores Garcia-Cosio Carmena, Esther Mancebo Sierra, Javier de Juan Baguda, Javier Castrodeza Calvo, Francisco Jose Hernandez Perez, Juan Francisco Delgado
Summary: Antibodies against donor-specific HLAs can be detected after heart transplantation and are crucial for long-term survival. However, there is a lack of consensus on the appropriate action to take after their detection. Treatment is typically initiated when antibody-mediated rejection occurs, but some antibodies may appear years before graft failure is detected, leading to irreversible damage.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Infectious Diseases
Nadir Arber, Pallav L. Shah, Lambert Assoumou, Casper Rokx, Nathalie De Castro, Ameet Bakhai, Alex Soriano Viladomiu, Lourdes Mateu, Carlos Lumbreras, Vicente Estrada, Adrian Curran, Pierre-Olivier Sellier, Annie Duffy, Carl Fletcher, Essy Mozaffari, Richard Haubrich, Paul Hodgkins, Anton Pozniak, Francois Raffi
Summary: This study found that COVID-19 patients treated with remdesivir on high flow oxygen therapy had higher mortality rates and longer hospital stays compared to patients on low flow oxygen or no supplemental oxygen. Early initiation of remdesivir upon admission was associated with a lower risk of death.
INFECTIOUS DISEASES NOW
(2023)
